preview

Development Of Resistance For Patients With Hiv / Aids Globally

Better Essays

Rupinder Sekhon Development of Resistance to Antifungal agents in candidiasis

Introduction
Candidiasis is a concern for patients with HIV/AIDS globally. The Literature data point out that this opportunistic pathogen is the leading cause of superficial and disseminated fungal infections in humans. 96% mycoses infection are caused by the Candida species1,2,3. In a healthy person, the Candida colonies that exist are mainly on mucosal surfaces of the oral cavity, gastrointestinal and urogenital tracts without showing any disease symptoms are most frequently identified as Candida species such as Candida Albicans (70%) and Candida Glabrata (7%)3,4,5,6,7. In immunocompromised humans, Candida frequently causes infections ranging from superficial mucosal lesions to disseminated or infection within the bloodstream6. Candida Albicans is the most common cause of hematogenously disseminated and fungemia. Candida albicans cause superficial infections that includes oral and vaginal thrush as well as chronic mucocutaneous candidiasis8. Being an important causative agent, it makes the condition difficult to treat and morbidity, superficial candidiasis of the skin, mucosa and nails have become a significant problem worldwide9. Although superficial candidiasis rarely presents a risk to the life of patients, it significantly lowers the quality of life9,10. Significantly high frequency of the occurrence of candidiasis, along with careful treatment.

Get Access